Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis.
Mouse models of the GM2 gangliosidoses [Tay-Sachs, late onset Tay-Sachs (LOTS), Sandhoff] and GM1 gangliosidosis have been studied to determine whether there is a common neuro-inflammatory component to these disorders. During the disease course, we have: (i) examined the expression of a number of in...
Main Authors: | Jeyakumar, M, Thomas, R, Elliot-Smith, E, Smith, D, van der Spoel, A, d'Azzo, A, Perry, V, Butters, T, Dwek, R, Platt, F |
---|---|
Formato: | Journal article |
Idioma: | English |
Publicado em: |
2003
|
Registos relacionados
-
Beneficial effects of substrate reduction therapy in a mouse model of GM1 gangliosidosis.
Por: Elliot-Smith, E, et al.
Publicado em: (2008) -
GM1 Gangliosidosis—A Mini-Review
Por: Elena-Raluca Nicoli, et al.
Publicado em: (2021-09-01) -
N-butyldeoxygalactonojirimycin reduces postnatal cerebellar ganglioside content in a mouse model of GM1 gangliosidosis
Por: Kasperzyk, J, et al.
Publicado em: (2004) -
N-butyldeoxygalactonojirimycin reduces neonatal brain ganglioside content in a mouse model of GM1 gangliosidosis.
Por: Kasperzyk, J, et al.
Publicado em: (2004) -
Substrate reduction reduces gangliosides in postnatal cerebrum-brainstem and cerebellum in GM1 gangliosidosis mice
Por: J.L. Kasperzyk, et al.
Publicado em: (2005-04-01)